C4 Therapeutics Stock Fundamentals
| CCCC Stock | USD 2.03 0.01 0.50% |
C4 Therapeutics fundamentals help investors to digest information that contributes to C4 Therapeutics' financial success or failures. It also enables traders to predict the movement of CCCC Stock. The fundamental analysis module provides a way to measure C4 Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to C4 Therapeutics stock.
At present, C4 Therapeutics' Net Interest Income is projected to increase significantly based on the last few years of reporting. The current year's Interest Income is expected to grow to about 15.2 M, whereas Interest Expense is forecasted to decline to 0.00. CCCC | Select Account or Indicator |
C4 Therapeutics Company Operating Margin Analysis
C4 Therapeutics' Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Current C4 Therapeutics Operating Margin | (7.28) % |
Most of C4 Therapeutics' fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, C4 Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
| Competition |
CCCC Pretax Profit Margin
Pretax Profit Margin |
|
Based on the recorded statements, C4 Therapeutics has an Operating Margin of -7.284%. This is 79.24% lower than that of the Biotechnology sector and 93.5% lower than that of the Health Care industry. The operating margin for all United States stocks is 32.2% higher than that of the company.
C4 Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining C4 Therapeutics's current stock value. Our valuation model uses many indicators to compare C4 Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across C4 Therapeutics competition to find correlations between indicators driving C4 Therapeutics's intrinsic value. More Info.C4 Therapeutics is rated below average in return on equity category among its peers. It is rated fourth in return on asset category among its peers . At present, C4 Therapeutics' Return On Equity is projected to slightly decrease based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the C4 Therapeutics' earnings, one of the primary drivers of an investment's value.CCCC Operating Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses C4 Therapeutics' direct or indirect competition against its Operating Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of C4 Therapeutics could also be used in its relative valuation, which is a method of valuing C4 Therapeutics by comparing valuation metrics of similar companies.C4 Therapeutics is currently under evaluation in operating margin category among its peers.
C4 Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of C4 Therapeutics from analyzing C4 Therapeutics' financial statements. These drivers represent accounts that assess C4 Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of C4 Therapeutics' important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 1.4B | 1.5B | 288.3M | 280.5M | 322.5M | 306.4M | |
| Enterprise Value | 1.3B | 1.4B | 345.7M | 224.9M | 258.6M | 245.7M |
C4 Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, C4 Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to C4 Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
CCCC Fundamentals
| Return On Equity | -0.46 | ||||
| Return On Asset | -0.2 | ||||
| Profit Margin | (2.96) % | ||||
| Operating Margin | (7.28) % | ||||
| Current Valuation | (35.75 M) | ||||
| Shares Outstanding | 70.99 M | ||||
| Shares Owned By Insiders | 11.51 % | ||||
| Shares Owned By Institutions | 91.51 % | ||||
| Number Of Shares Shorted | 8.06 M | ||||
| Price To Book | 0.66 X | ||||
| Price To Sales | 4.05 X | ||||
| Revenue | 35.58 M | ||||
| Gross Profit | (75.05 M) | ||||
| EBITDA | (115.36 M) | ||||
| Net Income | (105.32 M) | ||||
| Cash And Equivalents | 307.78 M | ||||
| Cash Per Share | 6.29 X | ||||
| Total Debt | 133.62 M | ||||
| Debt To Equity | 0.25 % | ||||
| Current Ratio | 6.90 X | ||||
| Book Value Per Share | 3.06 X | ||||
| Cash Flow From Operations | (65.16 M) | ||||
| Short Ratio | 4.70 X | ||||
| Earnings Per Share | (1.52) X | ||||
| Price To Earnings To Growth | 0.07 X | ||||
| Target Price | 15.56 | ||||
| Number Of Employees | 110 | ||||
| Beta | 3.0 | ||||
| Market Capitalization | 144.11 M | ||||
| Total Asset | 349.6 M | ||||
| Retained Earnings | (633.7 M) | ||||
| Working Capital | 212.59 M | ||||
| Current Asset | 1 K | ||||
| Current Liabilities | 49 K | ||||
| Net Asset | 349.6 M |
About C4 Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze C4 Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of C4 Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of C4 Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 17.8 M | 27.2 M | |
| Total Revenue | 35.6 M | 32.6 M | |
| Cost Of Revenue | 135.4 M | 142.1 M | |
| Stock Based Compensation To Revenue | 1.18 | 1.24 | |
| Sales General And Administrative To Revenue | 1.82 | 1.92 | |
| Research And Ddevelopement To Revenue | 5.10 | 5.36 | |
| Capex To Revenue | 0.07 | 0.07 | |
| Revenue Per Share | 0.48 | 0.85 | |
| Ebit Per Revenue | (7.70) | (7.32) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether C4 Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of C4 Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of C4 Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on C4 Therapeutics Stock:Check out C4 Therapeutics Piotroski F Score and C4 Therapeutics Altman Z Score analysis. For information on how to trade CCCC Stock refer to our How to Trade CCCC Stock guide.You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of C4 Therapeutics. If investors know CCCC will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about C4 Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.52) | Revenue Per Share | Quarterly Revenue Growth 0.588 | Return On Assets | Return On Equity |
The market value of C4 Therapeutics is measured differently than its book value, which is the value of CCCC that is recorded on the company's balance sheet. Investors also form their own opinion of C4 Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is C4 Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because C4 Therapeutics' market value can be influenced by many factors that don't directly affect C4 Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between C4 Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if C4 Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, C4 Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.